Business Combination - Summary of Final Purchase Price Allocation to Fair Value of Assets and Liabilities Acquired (Details) - Kuur Therapeutics, Inc. - USD ($) $ in Thousands	May 04, 2021	Jun. 30, 2022	Dec. 31, 2021
Allocation of Consideration:
Contingent consideration		$ 24,129	$ 24,076
Merger Agreement
Allocation of Consideration:
Stock issued (14,228,066 shares at $3.71)	$ 52,786
Contingent consideration	19,839
Purchase price:	72,625
Net assets acquired:
Cash and cash equivalents	1,425
Prepaid expenses and other current assets	133
In-process research & development	64,900
Accounts payable	(39)
Accrued expenses	(1,037)
Deferred income tax liability	(12,543)
Transaction incentive liability	(8,925)
Total identifiable net assets	43,914
Goodwill	28,711
Total purchase price allocation	$ 72,625